An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Subscribe To Our Newsletter & Stay Updated
